📊 CMMB Key Takeaways
Is Chemomab Therapeutics Ltd. (CMMB) a Good Investment?
Chemomab is a pre-revenue pharmaceutical company with significant cash burn and negative profitability, but maintains a strong balance sheet with $20.8M cash providing runway. The company is at a critical inflection point where clinical development progress and regulatory milestones will determine viability, presenting high execution risk typical of early-stage biotech.
Chemomab Therapeutics appears to be a pre-revenue biotech with no reported revenue or gross profit and ongoing operating and net losses, which makes the fundamental story heavily dependent on future clinical and regulatory execution rather than current business performance. The balance sheet is relatively clean, with $20.77M in cash, no meaningful debt, and a strong current ratio, but negative operating cash flow and weak returns on assets and equity indicate continued cash burn. Fundamentally, this is a financially solvent but highly speculative company with limited evidence of durable growth quality at the reported date.
Why Buy Chemomab Therapeutics Ltd. Stock? CMMB Key Strengths
- Strong cash position of $20.8M with minimal debt provides runway for clinical development
- Excellent liquidity with 4.83x current ratio indicating ability to meet short-term obligations
- Zero debt/equity ratio eliminates refinancing and solvency risks
- Strong liquidity with $20.77M in cash and a 4.83x current ratio
- No meaningful long-term debt, reducing balance sheet risk
- Equity base remains solid relative to liabilities, with $27.95M in stockholders equity
CMMB Stock Risks: Chemomab Therapeutics Ltd. Investment Risks
- Pre-revenue status with no commercial product generating income, entirely dependent on funding and cash reserves
- Severe cash burn of -$7.2M in operating cash flow demonstrates unsustainable burn rate relative to cash reserves
- Negative ROE of -31.3% and ROA of -25.0% indicate shareholder value destruction and asset inefficiency
- No revenue generation capability visible in current financial metrics creates existential business model risk
- Minimal insider trading activity (0 Form 4 filings in 90 days) suggests limited management confidence or activity
- No reported revenue, indicating the business is not yet commercially validated
- Persistent operating and net losses with negative free cash flow point to ongoing cash burn
- Financial data is stale as of 2023-03-31, increasing uncertainty around current runway and operating trajectory
Key Metrics to Watch
- Quarterly operating cash burn rate and runway estimate based on current cash reserves
- Clinical trial progression, regulatory milestones, and FDA/EMA pathway updates
- Future financing activities and dilution impact from capital raises
- Quarterly operating cash burn relative to cash balance
- Any transition from pre-revenue status to sustainable product or collaboration revenue
Chemomab Therapeutics Ltd. (CMMB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.83x current ratio provides a solid financial cushion.
CMMB Profit Margin, ROE & Profitability Analysis
CMMB vs Healthcare Sector: How Chemomab Therapeutics Ltd. Compares
How Chemomab Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Chemomab Therapeutics Ltd. Stock Overvalued? CMMB Valuation Analysis 2026
Based on fundamental analysis, Chemomab Therapeutics Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Chemomab Therapeutics Ltd. Balance Sheet: CMMB Debt, Cash & Liquidity
CMMB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Chemomab Therapeutics Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.06 reflects profitable operations.
CMMB Revenue Growth, EPS Growth & YoY Performance
Chemomab Therapeutics Ltd. Dividends, Buybacks & Capital Allocation
CMMB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Chemomab Therapeutics Ltd. (CIK: 0001534248)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CMMB
What is the AI rating for CMMB?
Chemomab Therapeutics Ltd. (CMMB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMMB's key strengths?
Claude: Strong cash position of $20.8M with minimal debt provides runway for clinical development. Excellent liquidity with 4.83x current ratio indicating ability to meet short-term obligations. ChatGPT: Strong liquidity with $20.77M in cash and a 4.83x current ratio. No meaningful long-term debt, reducing balance sheet risk.
What are the risks of investing in CMMB?
Claude: Pre-revenue status with no commercial product generating income, entirely dependent on funding and cash reserves. Severe cash burn of -$7.2M in operating cash flow demonstrates unsustainable burn rate relative to cash reserves. ChatGPT: No reported revenue, indicating the business is not yet commercially validated. Persistent operating and net losses with negative free cash flow point to ongoing cash burn.
What is CMMB's revenue and growth?
Chemomab Therapeutics Ltd. reported revenue of N/A.
Does CMMB pay dividends?
Chemomab Therapeutics Ltd. does not currently pay dividends.
Where can I find CMMB SEC filings?
Official SEC filings for Chemomab Therapeutics Ltd. (CIK: 0001534248) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMMB's EPS?
Chemomab Therapeutics Ltd. has a diluted EPS of $0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CMMB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Chemomab Therapeutics Ltd. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CMMB stock overvalued or undervalued?
Valuation metrics for CMMB: ROE of -31.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CMMB stock in 2026?
Our dual AI analysis gives Chemomab Therapeutics Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CMMB's free cash flow?
Chemomab Therapeutics Ltd.'s operating cash flow is $-7.2M, with capital expenditures of $1.0K.
How does CMMB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -31.3% (avg: 15%), current ratio 4.83 (avg: 2).